A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response

Richard Press, Chad Galderisi, Rui Yang, Carole Rempfer, Stephanie G. Willis, Michael J. Mauro, Brian Druker, Michael W N Deininger

Research output: Contribution to journalArticle

102 Citations (Scopus)

Abstract

Purpose: Imatinib induces a complete cytogenetic response (CCR) inmost chronic myeloid leukemia patients in chronic phase. Although CCR is usually durable, a minority of patients relapse. Biomarkers capable of predicting those CCR patients with a higher risk of relapse would improve therapeutic management. Experimental Design: To assess whether changes in BCR-ABL RNA levels are a prognostic biomarker predictive of relapse, we regularly monitored transcript levels [every 3 months (median)] in 90 patients with CCR during 49 months (median) of imatinib therapy. Results: Throughout follow-up, the 20 patients with eventual relapse had higher transcript levels than the durable responders. Major molecular response (MMR; >3-log reduction of BCR-ABL RNA) was attained by 76 patients (12 with subsequent relapse) and was a significant predictor of prolonged relapse-free survival (P = 0.0008). A minimal 0.5-log increase in transcripts (before relapse; experienced by 42 patients, 16 with subsequent relapse) conveyed a significantly shorter relapse-free survival (P = 0.0017). Loss of MMR (transcript increase to

Original languageEnglish (US)
Pages (from-to)6136-6143
Number of pages8
JournalClinical Cancer Research
Volume13
Issue number20
DOIs
StatePublished - Oct 15 2007

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cytogenetics
RNA
Recurrence
Biomarkers
Imatinib Mesylate
Survival
Research Design
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. / Press, Richard; Galderisi, Chad; Yang, Rui; Rempfer, Carole; Willis, Stephanie G.; Mauro, Michael J.; Druker, Brian; Deininger, Michael W N.

In: Clinical Cancer Research, Vol. 13, No. 20, 15.10.2007, p. 6136-6143.

Research output: Contribution to journalArticle

Press, Richard ; Galderisi, Chad ; Yang, Rui ; Rempfer, Carole ; Willis, Stephanie G. ; Mauro, Michael J. ; Druker, Brian ; Deininger, Michael W N. / A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. In: Clinical Cancer Research. 2007 ; Vol. 13, No. 20. pp. 6136-6143.
@article{d358284d07aa4c06a9ceec3dfc4e01f1,
title = "A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response",
abstract = "Purpose: Imatinib induces a complete cytogenetic response (CCR) inmost chronic myeloid leukemia patients in chronic phase. Although CCR is usually durable, a minority of patients relapse. Biomarkers capable of predicting those CCR patients with a higher risk of relapse would improve therapeutic management. Experimental Design: To assess whether changes in BCR-ABL RNA levels are a prognostic biomarker predictive of relapse, we regularly monitored transcript levels [every 3 months (median)] in 90 patients with CCR during 49 months (median) of imatinib therapy. Results: Throughout follow-up, the 20 patients with eventual relapse had higher transcript levels than the durable responders. Major molecular response (MMR; >3-log reduction of BCR-ABL RNA) was attained by 76 patients (12 with subsequent relapse) and was a significant predictor of prolonged relapse-free survival (P = 0.0008). A minimal 0.5-log increase in transcripts (before relapse; experienced by 42 patients, 16 with subsequent relapse) conveyed a significantly shorter relapse-free survival (P = 0.0017). Loss of MMR (transcript increase to",
author = "Richard Press and Chad Galderisi and Rui Yang and Carole Rempfer and Willis, {Stephanie G.} and Mauro, {Michael J.} and Brian Druker and Deininger, {Michael W N}",
year = "2007",
month = "10",
day = "15",
doi = "10.1158/1078-0432.CCR-07-1112",
language = "English (US)",
volume = "13",
pages = "6136--6143",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response

AU - Press, Richard

AU - Galderisi, Chad

AU - Yang, Rui

AU - Rempfer, Carole

AU - Willis, Stephanie G.

AU - Mauro, Michael J.

AU - Druker, Brian

AU - Deininger, Michael W N

PY - 2007/10/15

Y1 - 2007/10/15

N2 - Purpose: Imatinib induces a complete cytogenetic response (CCR) inmost chronic myeloid leukemia patients in chronic phase. Although CCR is usually durable, a minority of patients relapse. Biomarkers capable of predicting those CCR patients with a higher risk of relapse would improve therapeutic management. Experimental Design: To assess whether changes in BCR-ABL RNA levels are a prognostic biomarker predictive of relapse, we regularly monitored transcript levels [every 3 months (median)] in 90 patients with CCR during 49 months (median) of imatinib therapy. Results: Throughout follow-up, the 20 patients with eventual relapse had higher transcript levels than the durable responders. Major molecular response (MMR; >3-log reduction of BCR-ABL RNA) was attained by 76 patients (12 with subsequent relapse) and was a significant predictor of prolonged relapse-free survival (P = 0.0008). A minimal 0.5-log increase in transcripts (before relapse; experienced by 42 patients, 16 with subsequent relapse) conveyed a significantly shorter relapse-free survival (P = 0.0017). Loss of MMR (transcript increase to

AB - Purpose: Imatinib induces a complete cytogenetic response (CCR) inmost chronic myeloid leukemia patients in chronic phase. Although CCR is usually durable, a minority of patients relapse. Biomarkers capable of predicting those CCR patients with a higher risk of relapse would improve therapeutic management. Experimental Design: To assess whether changes in BCR-ABL RNA levels are a prognostic biomarker predictive of relapse, we regularly monitored transcript levels [every 3 months (median)] in 90 patients with CCR during 49 months (median) of imatinib therapy. Results: Throughout follow-up, the 20 patients with eventual relapse had higher transcript levels than the durable responders. Major molecular response (MMR; >3-log reduction of BCR-ABL RNA) was attained by 76 patients (12 with subsequent relapse) and was a significant predictor of prolonged relapse-free survival (P = 0.0008). A minimal 0.5-log increase in transcripts (before relapse; experienced by 42 patients, 16 with subsequent relapse) conveyed a significantly shorter relapse-free survival (P = 0.0017). Loss of MMR (transcript increase to

UR - http://www.scopus.com/inward/record.url?scp=35948937212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35948937212&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-07-1112

DO - 10.1158/1078-0432.CCR-07-1112

M3 - Article

C2 - 17947479

AN - SCOPUS:35948937212

VL - 13

SP - 6136

EP - 6143

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 20

ER -